|
1
|
Xue H, Wang H, Liu J, Liu H, Li C, Han L,
Lin C, Zhan Q, Zhao Z and Qian H: MTA1 downregulation inhibits
malignant potential in a small cell lung cancer cell line. Oncol
Rep. 33:885–892. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bremnes RM, Sundstrom S, Aasebø U, Kaasa
S, Hatlevoll R and Aamdal S: Norweigian Lung Cancer Study Group:
The value of prognostic factors in small cell lung cancer: Results
from a randomised multicenter study with minimum 5 year follow-up.
Lung Cancer. 39:303–313. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wood L, Palmer M, Hewitt J, Urtasun R,
Bruera E, Rapp E and Thaell JF: Results of a phase III,
double-blind, placebo-controlled trial of megestrol acetate
modulation of P-glycoprotein-mediated drug resistance in the
first-line management of small-cell lung carcinoma. Br J Cancer.
77:627–631. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Barger JF and Nana-Sinkam SP: MicroRNA as
tools and therapeutics in lung cancer. Respir Med. 109:803–812.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Che C, Zhang L, Huo J and Zhang Y: RNA
interference targeting enhancer of polycomb1 exerts anti-tumor
effects in lung cancer. Int J Clin Exp Pathol. 8:361–367.
2015.PubMed/NCBI
|
|
6
|
Joshi P, Middleton J, Jeon YJ and Garofalo
M: MicroRNAs in lung cancer. World J Methodol. 4:59–72. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huang Y, Hu Q, Deng Z, Hang Y, Wang J and
Wang K: MicroRNAs in body fluids as biomarkers for non-small cell
lung cancer: A systematic review. Technol Cancer Res Treat.
13:277–287. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ferjančič Š, Gil-Bernabé AM, Hill SA,
Allen PD, Richardson P, Sparey T, Savory E, McGuffog J and Muschel
RJ: VCAM-1 and VAP-1 recruit myeloid cells that promote pulmonary
metastasis in mice. Blood. 121:3289–3297. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang X, He D, Ming J, He Y, Zhou C, Ren
H, He X, Wang C, Jin J, Ji L, et al: High-density lipoprotein of
patients with breast cancer complicated with type 2 diabetes
mellitus promotes cancer cells adhesion to vascular endothelium via
ICAM-1 and VCAM-1 upregulation. Breast Cancer Res Treat.
155:441–455. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tas F, Karabulut S, Bilgin E and
Duranyildiz D: Serum levels of vascular cell adhesion molecule-1
(VCAM-1) may have diagnostic, predictive, and prognostic roles in
patients with lung cancer treated with platinum-based chemotherapy.
Tumour Biol. 35:7871–7875. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bharti S, Rani N, Krishnamurthy B and Arya
DS: Preclinical evidence for the pharmacological actions of
naringin: A review. Planta Med. 80:437–451. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kanno S, Shouji A, Asou K and Ishikawa M:
Effects of naringin on hydrogen peroxide-induced cytotoxicity and
apoptosis in P388 cells. J Pharmacol Sci. 92:166–170. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Camargo CA, Gomes-Marcondes MC, Wutzki NC
and Aoyama H: Naringin inhibits tumor growth and reduces
interleukin-6 and tumor necrosis factor α levels in rats with
Walker 256 carcinosarcoma. Anticancer Res. 32:129–133.
2012.PubMed/NCBI
|
|
14
|
Yang J, Chen L, Ding J, Zhang J, Fan Z,
Yang C, Yu Q and Yang J: Cardioprotective effect of miRNA-22 on
hypoxia/reoxygenation induced cardiomyocyte injury in neonatal
rats. Gene. 579:17–22. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kawaguchi T, Ando M, Asami K, Okano Y,
Fukuda M, Nakagawa H, Ibata H, Kozuki T, Endo T, Tamura A, et al:
Randomized phase III trial of erlotinib versus docetaxel as second-
or third-line therapy in patients with advanced non-small-cell lung
cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin
Oncol. 32:1902–1908. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gitlitz BJ, Tsao-Wei DD, Groshen S, Davies
A, Koczywas M, Belani CP, Argiris A, Ramalingam S, Vokes EE,
Edelman M, et al: A phase II study of halichondrin B analog
eribulin mesylate (E7389) in patients with advanced non-small cell
lung cancer previously treated with a taxane: A California cancer
consortium trial. J Thorac Oncol. 7:574–578. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gohagan J, Marcus P, Fagerstrom R, Pinsky
P, Kramer B and Prorok P: Writing Committee, Lung Screening Study
Research Group: Baseline findings of a randomized feasibility trial
of lung cancer screening with spiral CT scan vs chest radiograph:
The Lung Screening Study of the National Cancer Institute. Chest.
126:114–121. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zeng L, Zhen Y, Chen Y, Zou L, Zhang Y, Hu
F, Feng J, Shen J and Wei B: Naringin inhibits growth and induces
apoptosis by a mechanism dependent on reduced activation of
NF-κB/COX-2-caspase-1 pathway in HeLa cervical cancer cells. Int J
Oncol. 45:1929–1936. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li H, Yang B, Huang J, Xiang T, Yin X, Wan
J, Luo F, Zhang L, Li H and Ren G: Naringin inhibits growth
potential of human triple-negative breast cancer cells by targeting
β-catenin signaling pathway. Toxicol Lett. 220:219–228. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kanno S, Shouji A, Hirata R, Asou K and
Ishikawa M: Effects of naringin on cytosine arabinoside
(Ara-C)-induced cytotoxicity and apoptosis in P388 cells. Life Sci.
75:353–365. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang W, Zhang Q, Zhang M, Zhang Y, Li F
and Lei P: Analysis for the mechanism between the small cell lung
cancer and non-small cell lung cancer combing the miRNA and mRNA
expression profiles. Thorac Cancer. 6:70–79. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tan TW, Chou YE, Yang WH, Hsu CJ, Fong YC
and Tang CH: Naringin suppress chondrosarcoma migration through
inhibition vascular adhesion molecule-1 expression by modulating
miR-126. Int Immunopharmacol. 22:107–114. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fumarola C, Bonelli MA, Petronini PG and
Alfieri RR: Targeting PI3K/AKT/mTOR pathway in non small cell lung
cancer. Biochem Pharmacol. 90:197–207. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Poornima P, Weng CF and Padma VV: Neferine
from Nelumbo nucifera induces autophagy through the inhibition of
PI3K/Akt/mTOR pathway and ROS hyper generation in A549 cells. Food
Chem. 141:3598–3605. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Papadimitrakopoulou V: Development of
PI3K/AKT/mTOR pathway inhibitors and their application in
personalized therapy for non-small-cell lung cancer. J Thorac
Oncol. 7:1315–1326. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Choi UJ, Jee BK, Lim Y and Lee KH:
KAI1/CD82 decreases Rac1 expression and cell proliferation through
PI3K/Akt/mTOR pathway in H1299 lung carcinoma cells. Cell Biochem
Funct. 27:40–47. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee EJ, Kim DI, Kim WJ and Moon SK:
Naringin inhibits matrix metalloproteinase-9 expression and AKT
phosphorylation in tumor necrosis factor-alpha-induced vascular
smooth muscle cells. Mol Nutr Food Res. 53:1582–1591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Visweswaran GR, Gholizadeh S, Ruiters MH,
Molema G, Kok RJ and Kamps JA: Targeting rapamycin to podocytes
using a Vascular Cell Adhesion Molecule-1 (VCAM-1)-harnessed
SAINT-based lipid carrier system. PLoS One. 10:e01388702015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yurdagul A Jr, Sulzmaier FJ, Chen XL,
Pattillo CB, Schlaepfer DD and Orr AW: Oxidized LDL induces
FAK-dependent RSK signaling to drive NF-κB activation and VCAM-1
expression. J Cell Sci. 129:1580–1591. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gong L, Mi HJ, Zhu H, Zhou X and Yang H:
P-selectin-mediated platelet activation promotes adhesion of
non-small cell lung carcinoma cells on vascular endothelial cells
under flow. Mol Med Rep. 5:935–942. 2012. View Article : Google Scholar : PubMed/NCBI
|
